OrbiMed’s scPharmaceuticals SCPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-6,059,528
| Closed | -$34.4M | – | 125 |
|
|
2025
Q3 | $34.4M | Hold |
6,059,528
| – | – | 0.81% | 38 |
|
|
2025
Q2 | $23.1M | Hold |
6,059,528
| – | – | 0.58% | 41 |
|
|
2025
Q1 | $15.9M | Hold |
6,059,528
| – | – | 0.38% | 50 |
|
|
2024
Q4 | $21.5M | Hold |
6,059,528
| – | – | 0.44% | 52 |
|
|
2024
Q3 | $27.6M | Buy |
6,059,528
+500,000
| +9% | +$2.42M | 0.5% | 51 |
|
|
2024
Q2 | $24.2M | Hold |
5,559,528
| – | – | 0.48% | 53 |
|
|
2024
Q1 | $27.9M | Hold |
5,559,528
| – | – | 0.51% | 54 |
|
|
2023
Q4 | $34.9M | Hold |
5,559,528
| – | – | 0.7% | 52 |
|
|
2023
Q3 | $39.6M | Hold |
5,559,528
| – | – | 0.84% | 44 |
|
|
2023
Q2 | $56.7M | Hold |
5,559,528
| – | – | 1.03% | 38 |
|
|
2023
Q1 | $50.4M | Hold |
5,559,528
| – | – | 0.99% | 34 |
|
|
2022
Q4 | $39.9M | Buy |
5,559,528
+762,380
| +16% | +$4.66M | 0.76% | 48 |
|
|
2022
Q3 | $31.3M | Hold |
4,797,148
| – | – | 0.58% | 56 |
|
|
2022
Q2 | $23.1M | Hold |
4,797,148
| – | – | 0.42% | 57 |
|
|
2022
Q1 | $27.2M | Hold |
4,797,148
| – | – | 0.44% | 56 |
|
|
2021
Q4 | $24.1M | Hold |
4,797,148
| – | – | 0.31% | 78 |
|
|
2021
Q3 | $31.9M | Hold |
4,797,148
| – | – | 0.35% | 75 |
|
|
2021
Q2 | $29.3M | Hold |
4,797,148
| – | – | 0.3% | 78 |
|
|
2021
Q1 | $31.9M | Hold |
4,797,148
| – | – | 0.3% | 79 |
|
|
2020
Q4 | $25.4M | Hold |
4,797,148
| – | – | 0.22% | 90 |
|
|
2020
Q3 | $35.7M | Hold |
4,797,148
| – | – | 0.45% | 60 |
|
|
2020
Q2 | $35.3M | Buy |
4,797,148
+1,387,283
| +41% | +$12.2M | 0.5% | 59 |
|
|
2020
Q1 | $25.2M | Hold |
3,409,865
| – | – | 0.42% | 58 |
|
|
2019
Q4 | $19.3M | Hold |
3,409,865
| – | – | 0.28% | 67 |
|
|
2019
Q3 | $20M | Hold |
3,409,865
| – | – | 0.38% | 65 |
|
|
2019
Q2 | $10.9M | Hold |
3,409,865
| – | – | 0.17% | 91 |
|
|
2019
Q1 | $10.2M | Hold |
3,409,865
| – | – | 0.16% | 89 |
|
|
2018
Q4 | $12.8M | Hold |
3,409,865
| – | – | 0.24% | 80 |
|
|
2018
Q3 | $20M | Hold |
3,409,865
| – | – | 0.24% | 89 |
|
|
2018
Q2 | $19.3M | Hold |
3,409,865
| – | – | 0.23% | 94 |
|
|
2018
Q1 | $42.3M | Hold |
3,409,865
| – | – | 0.52% | 56 |
|
|
2017
Q4 | $41.2M | Buy |
+3,409,865
| New | +$48.1M | 0.52% | 60 |
|
OrbiMed's SCPH Position: Q4 2025 in Review
OrbiMed sold out of scPharmaceuticals (SCPH) in Q4 2025, closing a stake of 6,059,528 shares — an estimated $34.4M sold.
OrbiMed first reported a position in SCPH in Q4 2017 and held it in 32 quarters. The position peaked at $56.7M in Q2 2023. 0 funds tracked by Wall St. Rank hold SCPH as of Q4 2025.
- OrbiMed reported no remaining scPharmaceuticals position as of Q4 2025 after selling out during the quarter.
- OrbiMed sold 6,059,528 scPharmaceuticals shares in Q4 2025, an estimated $34.4M.
- OrbiMed first reported a position in scPharmaceuticals in Q4 2017 and held it in 32 quarters.
- OrbiMed's scPharmaceuticals position peaked at $56.7M in Q2 2023.
- 0 funds tracked by Wall St. Rank held scPharmaceuticals as of Q4 2025.
Based on OrbiMed's 13F filing for Q4 2025, filed 17 Feb 2026.